Role of GPRC5D in R/R MM Patients
January 18th 2024An expert briefly reviews the role of GPRC5C-targeting bispecifics in Relapsed/Refractory Multiple Myeloma (R/R MM) following four previous lines of therapy, comparing its efficacy and characteristics with other treatment options like BCMA and CAR-T therapies. She also provides insights into the benefits, risks, and potential challenges related to the access and utilization of GPRC5D-targeting bispecifics, providing a comprehensive overview of considerations in the advanced R/R MM treatment landscape.
Selecting The Appropriate Treatment in Transplant-Eligible Newly Diagnosed MM
January 30th 2023A brief discussion how to select the appropriate treatment strategy in transplant-eligible newly diagnosed myeloma and whether there is a role for minimal residual disease in assessing response and treatment duration.
Currently Available Treatment Options for Relapsed/Refractory Multiple Myeloma
November 17th 2022Dr Krina Patel presents the case of a relatively young patient with relapsed multiple myeloma, and Dr Caitlin Costello shares her approaches to treating relapsed/refractory multiple myeloma in her clinical practice.
Selecting a Treatment Regimen for Patients with Transplant-Eligible NDMM
October 27th 2022A panel of experts discusses whether all patients with multiple myeloma should undergo transplant, and how to select the optimal treatment regimens for the treatment of transplant-eligible newly-diagnosed multiple myeloma.
Induction Regimen Options for Patients with Transplant-Eligible NDMM
October 27th 2022Amrita Krishnan, MD, presents the case of a 63-year-old woman with transplant-eligible newly-diagnosed multiple myeloma, and Caitlin Costello, MD, describes the design and outcomes of recent trials in the transplant eligible setting.